Table 1 Results of univariable and multivariable Cox regression models for disease-free survival (DFS)
From: Prognostic relevance of molecular subtypes and master regulators in pancreatic ductal adenocarcinoma
Number of Patients | Disease-free Survival Time (DFS; median (CI): months) | Univariable | Multivariable | ||||
|---|---|---|---|---|---|---|---|
Hazard ratio (HR) (95% CI) | p-value | Hazard ratio (HR) (95% CI) | p-value | ||||
Clinicopathological Parameter | |||||||
Age | < 64 y. | 58 | 10.2 (6.4 - 13.3) | 0.756 (0.508 - 1.122) | 0.165 | ||
> 64 y. | 60 | 9.0 (7.3 - 10.9) | |||||
Gender | Female | 53 | 10.9 (8.1 - 13.5) | 0.785 (0.528 - 1.161) | 0.226 | ||
Male | 65 | 7.8 (6.0 - 11.1) | |||||
PDAC Location | Head | 93 | 9.8 (7.4 - 12.4) | 0.564 (0.357 - 0.921) | 0.023 | 0.581 (0.340 - 1.015) | 0.056 |
Body or Tail | 25 | 8.3 (4.4 - 11.1) | |||||
Tumor diameter | < 2 cm | 27 | 13.1 (6.7 - 17.0) | 0.676 (0.411 - 1.064) | 0.092 | 0.739 (0.399 - 1.306) | 0.306 |
> 2 cm | 91 | 7.8 (3.3 - 18.9) | |||||
pG | 1 | 10 | 13.1 (4.0 - 24.3) | 0.715 | |||
2 | 41 | 10.2 (7.1 - 16.2) | |||||
3 | 67 | 7.7 (6.0 - 11.0) | |||||
pT | 1 | 2 | 7.7 (7.3 - 8.1) | 0.857 | |||
2 | 13 | 11.6 (7.1 - 17.1) | |||||
3 | 95 | 9.0 (6.8 - 11.4) | |||||
4 | 8 | 8.4 (7.4 - 11.2) | |||||
pN | 0 | 45 | 10.3 (6.1 - 13.1) | 0.839 (0.557 - 1.248) | 0.39 | ||
1 | 73 | 8.8 (7.3 - 11.4) | |||||
pM | 0 | 105 | 10.0 (7.7 - 12.3) | 0.411 (0.230 - 0.802) | 0.011 | 0.441 (0.097 - 1.458) | 0.19 |
1 | 13 | 4.7 (3.2 - 10.9) | |||||
pR | 0 | 91 | 10.0 (7.8 - 12.4) | 0.712 (0.458 - 1.149) | 0.159 | ||
1 | 27 | 7.7 (7.4 - 11.2) | |||||
pRM | < 1 mm | 64 | 10.0 (6.3 - 13.1) | 0.925 (0.621 - 1.382) | 0.7 | ||
> 1 mm | 50 | 9.8 (7.0 - 12.3) | |||||
PNI | 0 | 15 | 17.1 (3.3 - 56.1) | 0.528 (0.264 - 0.955) | 0.034 | 0.516 (0.233 - 1.053) | 0.07 |
1 | 101 | 9.8 (7.4 - 11.4) | |||||
VI | 0 | 36 | 11.1 (7.0 - 18.9) | 0.629 (0.399 - 0.969) | 0.035 | 0.805 (0.485 - 1.303) | 0.382 |
1 | 76 | 8.0 (6.4 - 11.0) | |||||
LVI | 0 | 34 | 10.2 (6.1 - 14.3) | 0.833 (0.529 - 1.276) | 0.408 | ||
1 | 81 | 8.8 (7.3 - 11.4) | |||||
ECLNI | 0 | 69 | 10.4 (7.3 - 13.3) | 0.821 (0.544 - 1.254) | 0.356 | ||
1 | 43 | 8.4 (6.3 - 11.1) | |||||
AJCC TNM Stage 7th Ed. | ≤ 2a | 38 | 10.9 (6.8 - 14.3) | 0.730 (0.474 - 1.100) | 0.134 | ||
≥ 2b | 80 | 8.5 (7.0 - 11.1) | |||||
N0 <T3 M0 (Early) | 38 | 10.9 (6.8 - 14.3) | Early vs Adv 0.498 (0.273 - 0.950) | Overall 0.104 | Overall | 0.209 | |
N1 <T3 M0 (LNM) | 62 | 9.8 (7.3 - 12.6) | Early vs Adv 0.035 | 0.915 (0.295 - 4.022) | 0.892 | ||
T4 or M1 (Advanced) | 18 | 5 (3.3 - 10.4) | |||||
Adjuvant chemotherapy | 0 | 36 | 7.4 (4.6 - 11.0) | 1.139 (0.733 - 1.728) | 0.553 | ||
1 | 82 | 10.0 (7.7 - 12.6) | |||||
Molecular Subtypes | |||||||
k2 | Cluster 1 | 64 | 11.6 (7.4 - 16.2) | 0.655 (0.440 - 0.976) | 0.035 | 0.252 (0.092 - 0.888) | 0.034 |
Cluster 2 | 54 | 7.8 (6.7 - 10.0) | |||||
k3 | Cluster 1 | 42 | 13.5 (10.9 - 17.1) | Cl1 vs Cl2 0.602 (0.382 - 0.940) | Overall 0.053 | Overall | 0.318 |
Cluster 2 | 50 | 8.0 (7.0 - 10.0) | Cl1 vs Cl3 0.615 (0.363 - 1.066) | Cl1 vs Cl2 0.026 | |||
Cluster 3 | 26 | 4.7 (3.3 - 11.2) | Cl1 vs Cl3 0.082 | ||||
k4 | Cluster 1 | 39 | 13.3 (9.8 - 16.7) | Cl1 vs Cl2 0.670 (0.418 - 1.065) | Overall 0.333 | Overall | 0.751 |
Cluster 2 | 45 | 8.4 (6.7 - 10.0) | Cl1 vs Cl2 0.090 | ||||
Cluster 3 | 7 | 11.0 (4.8 - 17.1) | |||||
Cluster 4 | 27 | 4.7 (3.3 - 11.2) | |||||
k5 | Cluster 1 | 41 | 13.5 (10.9 - 17.0) | Cl1 vs Cl5 0.488 (0.251 - 1.021) | Overall 0.209 | Overall | 0.616 |
Cluster 2 | 35 | 8.4 (7.0 - 10.2) | Cl1 vs Cl5 0.057 | ||||
Cluster 3 | 4 | 9.3 (4.8 - NA) | |||||
Cluster 4 | 26 | 4.7 (3.3 - 11.2) | |||||
Cluster 5 | 12 | 7.5 (4.3 - 11.0) | |||||